Earlier therapeutic effects associated with high dose (2.0 mg) Ranibizumab for treatment of vascularized pigment epithelial detachments in age-related macular degeneration

Chan, Clement K.; Abraham, Prema; Sarraf, David; Nuthi, Asha S. D.; Lin, Steven G.; McCannel, Colin A.

doi:10.1038/eye.2014.233

Cited by 25 publications

(26 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Chan et al [43] recently reported results from a prospective study comparing the outcomes of 0.5 versus 2.0 mg intravitreal ranibizumab injections for treating vPED. The higher dose yielded more rapid reductions and more complete resolution of the PED; however, the incidence of RPE tear was higher in this group.…”

Section: Therapy In High-risk Patientsmentioning

confidence: 99%

Retinal Pigment Epithelium Tears: Risk Factors, Mechanism and Therapeutic Monitoring

2015

View full text Add to dashboard Cite

Tears of the retinal pigment epithelium (RPE) are most commonly associated with vascularised RPE detachment due to age-related macular degeneration (AMD), and they usually involve a deleterious loss in visual acuity. Recent studies suggest an increase in RPE tear incidences since the introduction of anti-vascular endothelial growth factor (anti-VEGF) therapies as well as a temporal association between the tear event and the intravitreal injection. As the number of AMD patients and the number of administered anti-VEGF injections increase, both the challenge of RPE tear prevention and the treatment after RPE tear formation have become more important. At the same time, the evolution of retinal imaging has significantly contributed to a better understanding of RPE tear development in recent years. This review summarises the current knowledge on RPE tear development, predictive factors, and treatment strategies before and after RPE tear formation.

show abstract

Section: Therapy In High-risk Patientsmentioning

confidence: 99%

Retinal Pigment Epithelium Tears: Risk Factors, Mechanism and Therapeutic Monitoring

2015

View full text Add to dashboard Cite

show abstract

“…; Chan et al. ). Our data indicate that there is a variable response to treatment, whereas overall there was a significant reduction in PED height.…”

Section: Discussionmentioning

confidence: 97%

Response of vascular pigment epithelium detachment due to age‐related macular degeneration to monthly treatment with ranibizumab: the prospective, multicentre RECOVER study

Clemens¹,

Wolf²,

Alten³

et al. 2017

Acta Ophthalmologica

View full text Add to dashboard Cite

Serous vascular PED lesions showed an improvement regarding BCVA and morphologic characteristics unless an RPE tear occurred. In fPED lesions, a functional and morphological stabilization was observed. Monthly ranibizumab injections are an effective treatment regarding the resorption of subretinal fluid in vPED due to AMD. Patients should be screened for the presence of morphologic risk factors for RPE tear development before and during treatment.

show abstract

“…During treatment, an individualized regime that is based on the patient's reaction is needed [19, 20]. For anti-VEGF drugs that have poor outcome, increasing the dosage, changing the drug, and combined treatment can be applied [21]. …”

Section: Discussionmentioning

confidence: 99%

Effects of Intravitreal Ranibizumab Injection on Chinese Patients with Wet Age-Related Macular Degeneration: 5-Year Follow-Up Results

Huang

Zhao

et al. 2016

Journal of Ophthalmology

View full text Add to dashboard Cite

Purpose. To observe the effect of intravitreal ranibizumab injection on wet age-related macular degeneration (wAMD) over 5 years in Chinese patients. Methods. Thirty-seven patients who were diagnosed with wAMD in our hospital from June 2007 to June 2014 were retrospectively reviewed. The PRN regimen and the treatment and extend regimen were applied. Best corrected visual acuity (BCVA), number of ranibizumab injections, and changes in the choroidal neovascularization (CNV) lesion over 5 years were analyzed. Results. The mean BCVA measured by the ETDRS chart at baseline was 47.4 and 5 years after the treatment it was 34.89 letters, which was significantly different (p = 0.013). Fourteen eyes (37.8%) had improved visual acuity after 5 years. The number of injections in 5 years was 11.53, and most of the injections were in the first two years. Seventeen (45.9%) cases developed fibrous lesions, and 2 (5.4%) cases had atrophic lesions after 5 years. The fibrosis/atrophy was significantly correlated with the injection numbers (Pearson, r = 0.663, and p = 0.000). Conclusion. Most of the patients can maintain visual acuity treated by ranibizumab in the first 3 years. After 5 years, some patients can still improve or maintain visual acuity. Fibrous scarring of the lesion is the main reason for a decrease in vision of wAMD patients.

show abstract

Earlier therapeutic effects associated with high dose (2.0 mg) Ranibizumab for treatment of vascularized pigment epithelial detachments in age-related macular degeneration

Cited by 25 publications

References 30 publications

Retinal Pigment Epithelium Tears: Risk Factors, Mechanism and Therapeutic Monitoring

Retinal Pigment Epithelium Tears: Risk Factors, Mechanism and Therapeutic Monitoring

Response of vascular pigment epithelium detachment due to age‐related macular degeneration to monthly treatment with ranibizumab: the prospective, multicentre RECOVER study

Effects of Intravitreal Ranibizumab Injection on Chinese Patients with Wet Age-Related Macular Degeneration: 5-Year Follow-Up Results

Contact Info

Product

Resources

About